<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856505</url>
  </required_header>
  <id_info>
    <org_study_id>00557</org_study_id>
    <nct_id>NCT00856505</nct_id>
  </id_info>
  <brief_title>Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Everolimus and Mycophenolate Sodium as GvHD Prophylaxis in Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In stem cell transplantation as treatment for malignant diseases, calcineurin inhibitors like
      cyclosporine A are commonly used to prevent tissue destruction (GvHD) by activated donor
      immune cells. The hypothesis for this study is, that replacing calcineurin inhibitors by
      everolimus and mycophenolate as GvHD prophylaxis not only reduces toxicity of the treatment
      but also improves tolerance induction of the donor T cells toward the host, eventually
      increasing the safety of stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity according to CTCAE v3.0</measure>
    <time_frame>after 100 days and one year after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic engraftment</measure>
    <time_frame>day 30 after stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GvHD</measure>
    <time_frame>one year after stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Day 100 and one year after stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>day 100 and one year after stem cell transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Everolimus and mycophenolate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of experimental immunosuppressants for GvHD prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus and mycophenolate sodium</intervention_name>
    <description>Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident</description>
    <arm_group_label>Everolimus and mycophenolate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hematologic malignancies, indicated for allogeneic stem cell
             transplantation:

          -  acute myeloid leukemia (AML), in CR1, ≥ CR2, primary refractory, relapse

          -  chronic myeloid leukemia (CML), in chronic phase, in acceleration or blast crisis

          -  myelodysplastic syndrome (MDS), RA/RARS (transfusion dependent), RAEB, RAEB-t and CMML

          -  Lymphoma:

               -  plasmocytoma

               -  immunocytoma (M. Waldenström)

               -  chronic-lymphatic leukemia (CLL)

               -  additional low and high grade Non-Hodgkin Lymphoma

          -  Hodgkins disease

          -  HLA-matched (HLA-A, -B, -DRB1) related or unrelated donor available

          -  Signed informed consent

        Exclusion Criteria:

          -  CNS involvement by underlying disease

          -  Pulmonary disease with VC &lt; 55%, DLCO &lt; 40%

          -  Cardiac ejection fraction &lt; 30%, uncontrollable arrhythmia

          -  Creatinin &gt; 1,5 mg/dl or Creatinin-Clearance &lt; 30 ml/min

          -  Bilirubin &gt; 2 mg/dl

          -  Active Hepatitis B or C

          -  HIV serologic positive

          -  Pregnancy and lactation

          -  Pre-menstrual women without medical safe contraception

          -  Participation on another clinical trial in between 30 days before start or during the
             study only if the clinical trial interferes with the outcome measures.

          -  Known allergy to study medication or ingredients of the formulation

          -  Drug- or alcohol abuse

          -  Non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Finke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Freiburg, Div. Hematology/Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhard Marks, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Freiburg, Div. Hematology/Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinhard Marks, MD</last_name>
    <phone>49-761-270-</phone>
    <phone_ext>3278</phone_ext>
    <email>reinhard.marks@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juergen Finke, MD</last_name>
    <phone>49-761-270-</phone>
    <phone_ext>3408</phone_ext>
    <email>juergen.finke@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center, Division Hematology/Oncology</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Marks, MD</last_name>
      <phone>49-761-270</phone>
      <phone_ext>3278</phone_ext>
      <email>reinhard.marks@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Reinhard Marks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Finke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <last_update_submitted>March 4, 2009</last_update_submitted>
  <last_update_submitted_qc>March 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Jürgen Finke</name_title>
    <organization>University Hospital Freiburg</organization>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

